FORM	4
------	---

-
Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

(Print or Type Re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person TRAVERSA SERGIO	2. Issuer Name and Actinium Pharma			0.5		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X. Director 10% Owner					
(Last) C/O ACTINIUM PHARMACEUTIC INC, 501 FIFTH AVENUE, THIRD	CALS,	3. Date of Earliest Transaction (Month/Day/Year) 08/08/2013						X_Officer (give title below)Other (specify below)			
(Street) NEW YORK, NY 10017		4. If Amendment, Da	ate Original	Filed	(Month/Day	//Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acqu						ired, Disposed of, or Beneficially Owned			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if	3. Transact Code (Instr. 8) Code		(A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or		of (D)	Transaction(s) (Instr. 3 and 4)	Ownership Form:	Beneficial Ownership	
Restricted Stock (1)	08/08/2013		А		10,000	А	\$ 3.6	0	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the

SEC 1474 (9-02)

contained in this form are not required to respond unless form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(<i>e.g.</i> , puts, calls, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Number		6. Date Exercisable and 7. Title and		l	8. Price of	9. Number of	10.	11. Nature	
Derivative	Conversion	Date	Execution Date, if	Transact	ion	of		Expiration I	Date	Amount of		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Derivativ	ve	(Month/Day	/Year)	Underlying Security		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8))	Securitie			Securities		(Instr. 5)	Beneficially	Derivative	Ownership	
	Derivative					Acquired	ł	(Instr. 3 ar						(Instr. 4)	
	Security					(A) or					0	Direct (D)			
						Disposed	1 of					1	or Indirect		
						(D)							Transaction(s)	· /	
						(Instr. 3,	4,						(Instr. 4)	(Instr. 4)	
						and 5)									
											Amount				
								Date	Expiration		or				
								Exercisable			Number				
				Cele	x 7						of				
				Code	v	(A)	(D)				Shares				
Options															
to										C					
purchase	\$ 3.6	08/08/2013		А		20,000		<u>(2)</u>	08/08/2023	Common stock	10.000	\$ 3.6	4,995	D	
common				-		.,				stock	.,		,		
stock															
STOCK															

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
TRAVERSA SERGIO C/O ACTINIUM PHARMACEUTICALS, INC 501 FIFTH AVENUE, THIRD FLOOR NEW YORK, NY 10017	х		Interim CFO					

Signatures

/s/ Sergio Traversa	12/24/2013
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 100% of the restricted stock will vest 12 months after the date of grant.

(2) Options granted on August 8, 2013 to purchase an aggregate of 20,000 shares of common stock. Options vest at a rate of 2% per month. As of the date of this report, 1,600 options have vested pursuant to the August 8, 2013 grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.